140 related articles for article (PubMed ID: 16264799)
1. Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer.
Pusztai L; Gianni L
Nat Clin Pract Oncol; 2004 Nov; 1(1):44-50. PubMed ID: 16264799
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
3. Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.
Malinowski DP
Expert Rev Mol Diagn; 2007 May; 7(3):269-80. PubMed ID: 17489734
[TBL] [Abstract][Full Text] [Related]
4. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer.
Nagasaki K; Miki Y
Breast Cancer; 2008; 15(2):117-20. PubMed ID: 18274834
[TBL] [Abstract][Full Text] [Related]
5. Gene-expression profiles, tumor microenvironment, and cancer stem cells in breast cancer: latest advances towards an integrated approach.
Vera-Ramirez L; Sanchez-Rovira P; Ramirez-Tortosa CL; Quiles JL; Ramirez-Tortosa MC; Alvarez JC; Fernandez-Navarro M; Lorente JA
Cancer Treat Rev; 2010 Oct; 36(6):477-84. PubMed ID: 20299155
[TBL] [Abstract][Full Text] [Related]
6. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
7. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological and genomics predictors of response to neoadjuvant chemotherapy in breast cancer].
Frati A; Lesieur B; Benbara A; Bezu C; Uzan S; Rouzier R; Coutant C
Gynecol Obstet Fertil; 2010; 38(7-8):475-80. PubMed ID: 20579923
[TBL] [Abstract][Full Text] [Related]
9. Molecular classification of breast cancer: limitations and potential.
Pusztai L; Mazouni C; Anderson K; Wu Y; Symmans WF
Oncologist; 2006 Sep; 11(8):868-77. PubMed ID: 16951390
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling in breast cancer.
Morris SR; Carey LA
Curr Opin Oncol; 2007 Nov; 19(6):547-51. PubMed ID: 17906450
[TBL] [Abstract][Full Text] [Related]
11. Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy.
Paik S
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1019s-1023s. PubMed ID: 16467119
[TBL] [Abstract][Full Text] [Related]
12. Primary systemic therapy of breast cancer.
Sachelarie I; Grossbard ML; Chadha M; Feldman S; Ghesani M; Blum RH
Oncologist; 2006 Jun; 11(6):574-89. PubMed ID: 16794237
[TBL] [Abstract][Full Text] [Related]
13. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
14. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
Correa Geyer F; Reis-Filho JS
Int J Surg Pathol; 2009 Aug; 17(4):285-302. PubMed ID: 19103611
[TBL] [Abstract][Full Text] [Related]
15. New molecular classifications of breast cancer.
Cianfrocca M; Gradishar W
CA Cancer J Clin; 2009; 59(5):303-13. PubMed ID: 19729680
[TBL] [Abstract][Full Text] [Related]
16. Current status of prognostic profiling in breast cancer.
Pusztai L
Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548
[TBL] [Abstract][Full Text] [Related]
17. Microarrays in breast cancer research and clinical practice--the future lies ahead.
Gruvberger-Saal SK; Cunliffe HE; Carr KM; Hedenfalk IA
Endocr Relat Cancer; 2006 Dec; 13(4):1017-31. PubMed ID: 17158752
[TBL] [Abstract][Full Text] [Related]
18. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
Ivanov O; Chen F; Wiley EL; Keswani A; Diaz LK; Memmel HC; Rademaker A; Gradishar WJ; Morrow M; Khan SA; Cryns VL
Breast Cancer Res Treat; 2008 Oct; 111(3):411-7. PubMed ID: 17968656
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling of breast cancer.
Paik S
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):59-63. PubMed ID: 16493262
[TBL] [Abstract][Full Text] [Related]
20. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
